Merck Points To Antibody-Drug Conjugate Potential During Another Growth Quarter

Keytruda brought in its usual stacks of cash, but Merck’s Q3 earnings call focused largely on a recent alliance with Daiichi Sankyo and the pharma’s growing emphasis on cancer ADCs.